Takeda Pharmaceutical Files 6-K Report

TL;DR

Takeda filed a 6-K, confirming its reporting status and Tokyo HQ. Nothing major, just housekeeping.

AI Summary

Takeda Pharmaceutical Company Limited filed a Form 6-K on July 2, 2024, to report information as a foreign private issuer for the month of July 2024. The filing indicates Takeda's principal executive offices are located in Tokyo, Japan, and confirms they file annual reports under Form 20-F.

Why It Matters

This filing serves as a routine update for investors and regulatory bodies, confirming Takeda's ongoing compliance and reporting status as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine administrative filing by Takeda, not indicating any new material events or risks.

Key Players & Entities

• Takeda Pharmaceutical Company Limited (company) — Filer of the 6-K report
• Tokyo, Japan (location) — Location of Takeda's principal executive offices

FAQ

Filing Documents

• form6k_070224.htm (6-K) — 60KB
• 0001395064-24-000104.txt ( ) — 61KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date July 2, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller Results of the Exercise of Voting Rights of the 148th Ordinary General Meeting of Shareholders 1. Reason for the submission The report is submitted pursuant to the provisions of Article 24-5, Paragraph 4 in the Financial Instruments and Exchange Act, and Article 19, Paragraph 2, Item 9-2 in the Cabinet Office Ordinance on Disclosure of Corporate Information, etc., which shows the results of the resolution on the matters to be resolved at the 148th Ordinary General Meeting of Shareholders of the Company held on June 26, 2024. 2. Contents 1 The date of the shareholders meeting June 26, 2024 2 Details of matters to be resolved First Proposal Appropriation of Surplus Concerning the year-end dividend 94yen per share of common stock of the Company Second Proposal Election of Ten (10) Directors who are not Audit and Supervisory Committee Members To elect Christophe Weber, Andrew Plump, Milano Furuta, Masami Iijima, Ian Clark, Steven Gillis, John Maraganore, Michel Orsinger, Miki Tsusaka and Emiko Higashi as Directors who are not Audit and Supervisory Committee Members. Third Proposal Election of Four (4) Directors who are Audit and Supervisory Committee Members To elect Koji Hatsukawa, Yoshiaki Fujimori, Kimberly A. Reed and Jean-Luc Butel as Directors who are Audit and Supervisory Committee Members. Fourth Proposal Payment of Bonuses to Directors who are not Audit and Supervisory Committee Members To pay bonuses within a total of 500 million yen to the 2 Directors who are not Audit and Supervisory Committee Members (excluding Directors residing outside of Japan and External Directors) in office as of the end of t

View Full Filing

View this 6-K filing on SEC EDGAR